Altimmune Aktie

2,26 EUR -0,07 EUR -2,80 %

18:17:50

STU

2,65 USD -0,08 USD -2,94 %

18:16:45

BTT

Altimmune jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.311,23 Mio. EUR

Div. Rendite0,00%

WKNA2N5Z6

ISINUS02155H2004

SymbolALT

Altimmune Aktien News

Sortieren:Datum Meistgelesen

23.04.26ZacksAltimmune Catalysts: 2026 Data Readouts and Financing Risks

23.04.26ZacksIs Altimmune a Buy Before Phase III MASH Starts in 2026?

23.04.26BenzingaWhy Is Altimmune Stock Falling Today?

WerbungAltimmune-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

26.03.26ZacksAltimmune Stock: Neutral Outlook With Big 2026 Catalysts

05.03.26MotleyFoolAltimmune (ALT) Q4 2025 Earnings Call Transcript

05.03.26BenzingaAltimmune: Q4 Earnings Insights

26.02.26MotleyFoolForget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play

28.01.26BenzingaAltimmune (ALT) Shares Slide On $75 Million Stock Offering

28.01.26BenzingaQorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

05.01.26BenzingaWhy Are Investors Looking At Altimmune Stock?

05.01.26BenzingaAltimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

11.12.25ZacksDoes Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?

25.11.25ZacksWall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know

10.10.25BenzingaAltimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

07.10.25PR NewswireALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

03.10.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

01.10.25PR NewswireAltimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

29.09.25PR NewswireALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

23.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

22.09.25PR NewswireALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

18.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

13.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

08.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

03.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

03.09.25PR NewswireALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

01.09.25PR NewswireALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

26.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

22.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

21.08.25PR NewswireINVESTOR REMINDER: Berger Montague Notifies Altimmune, Inc. (NASDAQ: ALT) Investors of a Class Action Lawsuit and Deadline

16.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

15.08.25PR NewswireBerger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

13.08.25BenzingaWhat 5 Analyst Ratings Have To Say About Altimmune

13.08.25BenzingaThese Analysts Slash Their Forecasts On Altimmune Following Q2 Results

12.08.25BenzingaAltimmune Q2 FY2025 Earnings Call Transcript

11.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

10.08.25PR NewswireALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

06.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

31.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

27.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

25.07.25ZacksAltimmune Gears Up to Report Q2 Earnings: Here's What to Expect

Altimmune News

Altimmune News: auf dieser Seite finden Sie alle Altimmune News und Nachrichten zur Altimmune Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Altimmune News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Altimmune News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.